Pharmacology articles

Balancear el riesgo de sangrado vs trombótico para definir el tiempo de doble antiagregación

Antiaggregation vs. Anticoagulation after Peripheral PCI

Antiaggregation vs. Anticoagulation after Peripheral PCI

The truth is this question has no clear answer and what with do with peripheral stenting is transfer the evidence we have on coronary stenting, given the lack of standards and poor reporting on antithrombotic therapy outcomes in randomized studies on endovascular intervention.  Heterogeneity is worse when it comes to venous territory. Some time ago

Efectos de la radiación cerebral en Cardiólogos Intervencionistas

Cerebrovascular Events After TAVR May Be Especially Serious

Stroke events do not seem to be related to valve thrombosis or structural degeneration, but to a higher baseline risk in patients who undergo transcatheter aortic valve replacement (TAVR). About 1 in 20 patients who underwent TAVR experienced a stroke or transient ischemic attack during follow-up. According to this new analysis, the consequences of these events

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

ECS Guidelines for COVID-19 Management

One of the first statements in this document points out these are not “regular guidelines” developed after thorough analysis of all the available evidence published since the last update. Instead, they are meant to provide temporary basic management pointers on how to handle different scenarios of cardiac patients in the context of the COVID-19 pandemic.

Doctor con tabletas de aspirinas

Are Non-Culprit Lesions Really Innocent?

In recent times, a lot has been said about reducing the duration or intensity of antiplatelet therapy following percutaneous coronary intervention (PCI) regardless initial indications. All evidence in support of these arguments might be failing to show the risk of non-culprit lesion events in patients with acute coronary syndromes (ACS). Potent and prolonged antithrombotic therapies

Una nueva molécula para evitar la nefropatía por contraste

A New Molecule to Prevent Contrast-Induced Kidney Injury

Administrating Recombinant Human C1-Esterase-Inhibitor (rhC1INH) before coronary angiography might mitigate contrast induced kidney injury. In addition, it shows a favorable safety profile in populations with multiple comorbidities.  The contrast material used in all our diagnostic tests and therapeutic procedures causes tubular cytotoxicity and ischemia/reperfusion injury. rhC1INH had been effective at mitigating this mechanism in experimental

Coronavirus y corazón ¿Cómo deben prepararse los cardiólogos?

Cardiology in Times of Coronavirus: The Perfect Storm

Since January 2020, the COVID-19 infection has spread from China to the rest of the world. The clinical picture has several points in common with influenza, being mild or asymptomatic in most cases. However, around 15% of cases shows complications with interstitial pneumonia that can lead to respiratory failure. Given the lack of vaccine or

ACC Virtual 2020 | TICO: monoterapia de ticagrelor en síndromes coronarios agudos

Virtual ACC 2020 | TICO: Ticagrelor Monotherapy in Acute Coronary Syndromes

Switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduces major bleeding without paying a price in terms of ischemic events, compared with dual antiplatelet therapy for a year, in patients who had acute coronary syndrome and underwent angioplasty with a second-generation drug-eluting stent. Interrupting aspirin at 3 months and switching it for ticagrelor reduces

ACC 2020 Virtual | PRONOMOS: Rivaroxaban superior a la enoxaparina en cirugías ortopédicas

Virtual ACC 2020 | PRONOMOS: Rivaroxaban Superior to Enoxaparin in Orthopedic Surgery

According to this new study presented virtually at the suspended American College of Cardiology (ACC) 2020 Scientific Session and published simultaneously in the New England Journal of Medicine (NEJM), rivaroxaban is more effective than enoxaparin in preventing venous thromboembolism during a period of immobilization after nonmajor orthopedic surgery of a lower limb. After an orthopedic

Virtual ACC 2020 | TWILIGHT-COMPLEX: Ticagrelor Monotherapy in the Most “Dangerous” Angioplasties

The original TWILIGHT findings in more than 9000 patients who underwent angioplasty were presented last year at TCT and showed a 3.1% absolute risk reduction in BARC 2, 3, or 5 bleeding with no increase in death, infarction, or stroke in patients who received ticagrelor and placebo compared with patients who received ticagrelor and aspirin. All patients